In Silico Immunogenicity Prediction

Biotherapeutic antibodies and proteins have the risk of causing anti-drug antibody responses in human bodies and fail to achieve desired therapeutic goals or cause allergic reactions.

Histocompatibility complex class II (MHC class II) are the key molecules to recognize the immunogenic peptides, presented as epitopes from the biotherapeutic molecules, on antigen presenting cells and imprint the T cell receptors for cascade responses.

Our in silico immunogenicity prediction service provides the cost-effective initial analysis of the immunogenicity of the biologics against the major MHC class II alleles. Using trained artificial neural network ensembles, 9 core residues with potential affinity to the binding cleft of MHC class II molecules are identified, providing important information for further engineering and optimization. 

Please contact LakePharma at for custom quotes and details.

Download Antibody Discovery brochure  Download PEGS Presentation - Integrated Solutions for Antibody Discovery and Beyond  View webinar: Discovery of Potent, Functional mAbs using Hybridoma and Phage Display Platforms Introduction to antibody libraries eBook


"LakePharma was a great partner; very helpful, focused, and committed. Thank you for your antibody engineering and production services which made this project a success."

- Maria Day, ImmuNext

LakePharma is proud to contribute to ImmuNext's success.
View their press release here


Cat.# Service Name Timeline Size Price Quantity Request
24701 In Silico Immunogenicity Prediction 4-5 days TBD Request

VH and VL are analyzed and nine core residues with potential affinity to the binding cleft of MHC class II molecules are identified.

Amino acid sequence of mature heavy and light chain variable regions